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Abstract 
Predictive Modeling Pilot Project for Readmissions in Heart Failure Patients 
with Preserved Ejection Fraction 
Pin Xiang, M.S.P.S 
The University of Texas at Austin, 2018 
   
Supervisor: Karen L. Rascati, James P. Wilson 
 
Objectives:  To pilot a predictive model evaluating hospital readmissions for heart 
failure with preserved ejection fraction (HFpEF) patients and the association with 
management by a cardiologist, number of comorbidities, and type of treatment. 
Methods:  This is a retrospective, observational study of claims data to evaluate the 
effect of various factors: age, gender, provider, baseline inpatient admissions, 
comorbidities and baseline drug treatment classes (e.g. antiarrhythmic, beta blocker, 
calcium channel blocker, diuretic, RAAS-inhibiting agents) on number of readmissions, 
time to readmission, and odds of readmission. Patients >18 years of age with an inpatient 
admission with a primary discharge diagnosis of HFpEF between October 1, 2011 and 
September 30, 2014 were identified and data were assessed 1-year pre- and post-
hospitalization. Patient characteristics were described, and patients treated by a 
cardiologist were compared to those who were not. Multivariate regression and Cox 
  vii 
proportional hazard models were used to assess the association of all-cause and heart 
failure-related readmissions adjusting for demographic and clinical covariates. 
Results: A total of 264 patients with HFpEF were identified (60.2% female; mean 
age of 79 years (SD 10.8) of which 77 [29%] did not see a cardiologist. Patients who saw 
a cardiologist were more likely to be male and had a greater number of comorbidities 
including diabetes, dyslipidemia, hypertension, coronary heart disease, cardiomyopathy, 
and valvular heart disease than those without cardiologist. Overall, 51% of the patients had 
an all-cause readmission and 15% had an HF-related readmission. Patients who had a 
cardiologist were associated with more all-cause readmissions (IRR of 2.21, p=0.0003) and 
a shorter time to all-cause readmissions (HR of 1.91, p=0.004). Being on diuretics was 
associated with more heart failure-related readmissions (IRR of 2.84, p=0.0301). A higher 
number of all-cause readmission was associated with patients having more comorbidities 
(IRR of 1.19, p=0.0038). 
Conclusion:    This study demonstrated that all-cause and heart failure-related 
readmission is high in patients with HFpEF. The pilot predictive models show that 
various factors associated with higher risk patients, such as those with cardiologist 
management, more comorbidities, and use of diuretics, may be associated with increased 
hospital readmissions.  
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CHAPTER 1: INTRODUCTION 
1.1 Background 
Heart failure (HF) or congestive heart failure (CHF) is characterized by the inability of the 
heart to pump blood well enough to meet the body’s need for blood and oxygen.1 There is a 
significant unmet need in the management of heart failure indicated by the high rate of 
hospitalization in the United States. Approximately 60% of all direct healthcare cost for heart 
failure is associated with hospitalization.2 Once hospitalized, patients are often rehospitalized for 
heart failure. This has become a point of focus in recent years as heart failure hospital readmissions 
have been implemented as a quality measure. In 2012, the Affordable Care Act established the 
Hospital Readmission Reduction Program, which penalized hospital with higher than expected 30-
day readmission rates for acute myocardial infarction, heart failure, and pneumonia.3  
The 2013 ACCF/AHA Heart Failure Guideline characterized heart failure (HF) into two 
groups: those with reduced ejection fraction (HFrEF) or with preserved ejection fraction (HFpEF).  
HFrEF is commonly referred to as systolic HF and occurs when the ejection fraction is less than 
40%. HFpEF is referred to as diastolic HF and occurs when ejection fraction is more than 50%. 
Those with EF between 41-49% is considered borderline HFpEF.1,4-8 Table 1.1 provides an in-
depth description. 
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Table 1.1 - Definitions of HFrEF and HFpEF1 
Classification EF (%) Description 
I.  Heart failure with     
reduced ejection fraction 
(HFrEF) 
≤ 40 Randomized controlled trials have mainly 
enrolled patients with HFrEF, and it is only in 
these patients that efficacious therapies have 
been demonstrated to date. 
II.  Heart failure with 
preserved ejection fraction 
(HFpEF) 
≥ 50 Several different criteria have been used to 
further define HFpEF. The diagnosis of HFpEF 
is challenging because it is largely one of 
excluding other potential noncardiac causes of 
symptoms suggestive of HF. To date, efficacious 
therapies have not been identified. 
     a. HFpEF, borderline 41 to 49 These patients fall into a borderline or 
intermediate group. Their characteristics, 
treatment patterns, and outcomes appear similar 
to those of patients with HFpEF 
      b. HFpEF, improved > 40 It has been recognized that a subset of patients 
with HFpEF previously had HFrEF. These 
patients with improvement or recovery in EF 
may be clinically distinct from those with 
persistently preserved or reduced EF. Further 
research is needed to better characterize these 
patients.  
EF- ejection fraction; HF, heart failure; HFpEF- heart failure with preserved ejection fraction; and HFrEF- heart 
failure with reduced ejection fraction 
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While symptoms of both types of heart failure often includes shortness of breath, fatigue 
or swelling in leg, the clinical characteristics and management of HFrEF and HFpEF is quite 
different. While HFrEF usually indicates a pumping problem where the left ventricle can’t contract 
vigorously enough (thus reduced ejection fraction), HFpEF is a filling problem where the left 
ventricle can’t relax or fill fully. Furthermore, most randomized controlled trials have 
predominantly enrolled patients with HFrEF and all proven efficacious treatments have only been 
demonstrated in this group. With no clear efficacious treatment identified, those with HFpEF is a 
highly underserved patient group and will be the focus of this study.5,9-11 
1.2 Epidemiology and Prevalence of Heart Failure 
The lifetime risk of developing heart failure (HF) is 20% for both men and women at age 
of 40 years and older.12 This burden is especially high among the elderly where the incidence 
and prevalence of Medicare patients (aged ≥ 65 years) with HF is approximately 29 and 121 per 
1,000 per years, respectively.13 Based on the 2017 Heart Disease and Stroke statistics put out by 
the American Heart Association, there is 960,000 new cases of HF annually. Based on 2011-
2014 NHANES data, approximately 6.5 million people greater than 20 years of age in the US 
have heart failure. It is projected that the total number of Americans living with HF will increase 
by 46% from 2012 to 2030, which is over 8 million people.14 
There were over 1 million hospital stays that had a principal diagnosis of HF in 2011 and 
over 500,000 emergency room visits the following year. Approximately 25% of hospitalized 
patients with HF are readmitted within 30 days of discharge and HF is the leading cause of 
rehospitalization in patients on Medicare. This leads to an estimated direct annual cost of $60 
billion when considered in isolation and $115 billion when considered as part of a syndrome.14-18 
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While more research has been conducted in patients with HFrEF, approximately 50% of 
the HF patients suffer from HFpEF (Figure 1.1). The latest data suggest that age-specific 
incidence of HF may be decreasing, but to a lesser extent in HFpEF than HFrEF. Furthermore, 
the risk of HFpEF increases sharply with age, which is a concern given the aging US population. 
Finally, multimorbidity is common in both types of HF but slightly more severe in HFpEF, 
where 50% of patients have five or more comorbidities.19-20  
 
 
 
Figure 1.1 – Distribution of left ventricular ejection fraction in incident heart failure20 
 
HFrEF- heart failure with reduced ejection fraction; HmrEF- heart failure with mid-range ejection fraction; HFpEF- 
heart failure with preserved ejection fraction.  
The distribution of ejection fraction in 1,223 patients with incident heart failure (defined by Framingham criteria) 
from Olmsted County, Minnesota, USA, according to sex.  
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1.3 Pathophysiology of Heart Failure 
Heart failure, by its name, may suggest the disorder of the heart but it is a multisystem 
disorder characterized by abnormalities of the heart muscle, skeletal muscle, endothelial 
function, renal function, sympathetic nervous system, and neurohormonal changes.21 It can be 
defined by the inability to provide sufficient blood output to meet the requirements from tissues 
while maintaining filling pressure. This can occur in two ways: 
- Systolic dysfunction (HFrEF) where there is impaired cardiac contractility – pumping 
problem 
- Diastolic dysfunction (HFpEF) where there is abnormal cardiac relaxation – filling problem 
The cause for heart failure from the damage of the heart muscle can be from a wide number of 
conditions such as myocardial infarction (heart attack), hypertension (high blood pressure), and 
amyloidosis (stiffening of heart muscle from protein deposits).22-26 
 More specifically, for heart failure with preserved ejection fraction, these patients often 
have significant remodeling that affects the left ventricular and left arterial chambers, the 
cardiomyocytes, and the extracellular matrix. Many patients with HFpEF undergo a concentric 
pattern of left ventricular chamber remodeling and a hypertrophic process  (see Figure 1.2).27-30   
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Figure 1.2 Pattern of left ventricular remodeling
 
▪ The schematic demonstrates the relationship between left ventricular (LV) end-diastolic volume (LVEDV, 
represented here by the size of the inner circle) and LV mass (LV mass, represented here by the size of the shaded 
region) for various patterns of remodeling. 
▪ Relative wall thickness (RWT) is the ratio of wall thickness to left ventricular diastolic dimension (RWT = 2x 
[diastolic posterior wall thickness]/left ventricular internal diastolic dimension). 
▪ With concentric remodeling, LVEDV is normal or reduced, LV mass is normal, and RWT is increased (and LV 
mass/LVEDV is increased). 
▪ With concentric hypertrophy, LVEDV is normal or reduced, LV mass is increased, and RWT is increased (and LV 
mass/LVEDV is increased). 
▪ With eccentric remodeling, LVEDV is increased, LV mass is normal to reduced, and RWT is normal to reduced 
(and LV mass/LVEDV is normal to reduced). 
▪ With eccentric hypertrophy, LVEDV is increased, LV mass is increased, and RWT is normal to reduced (and LV 
mass/LVEDV is normal to reduced). 
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1.4 Diagnosis of Heart Failure 
 The most common symptoms of heart failure are shortness of breath, fatigue, and fluid 
retention. This may lead to pulmonary congestion (difficulty breathing) and peripheral edema 
(swelling of the leg).1 The American College of Cardiology Foundation and the American Heart 
Association groups HF into 4 stages based on risk and progression31: 
A. At high risk for HF but without structural heart disease or symptoms of HF 
B. Structural heart disease but without signs or symptoms of HF 
C. Structural heart disease with prior or current symptoms of HF 
D. Refractory HF requiring specialized interventions 
Whereas the New York Heart Association groups HF in 4 classes based on severity31: 
I. No limitation of physical activity. Ordinary physical activity does not cause symptoms 
of HF 
II. Slight limitation of physical activity. Comfortable at rest, but ordinary physical 
activity results in symptoms of HF 
III. Marked limitation of physical activity. Comfortable at rest, but less than ordinary 
activity causes symptoms of HF 
IV. Unable to carry on any physical activity without symptoms of HF, or symptoms of 
HF at rest  
As discussed in the background, HFpEF and HFrEF are commonly differentiated based on 
the ejection fraction (EF) where EF ≤ 40% are HFrEF patients, EF≥50% are HFpEF patients, and 
EF between 41-49% are borderline HFpEF patients.1 However, HFpEF should be distinguished 
from other causes of HF with EF≥50% such as valvular heart disease, cardiomyopathy, 
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pericardial disease, and high output HF. Table 1.2 highlights differential diagnoses of HFpEF, 
where the signs and symptoms may be present but not included in the definition of HFpEF.  
Table 1.2 – Differential Diagnosis of HFpEF19 
Categories and Diagnosis 
Uncorrected primary left-sided valvular 
heart disease 
- Aortic stenosis 
- Aortic regurgitation 
- Mitral stenosis 
- Mitral regurgitation 
Pericardial disease 
- Tamponade 
- Constrictive pericarditis 
Isolated right ventricular failure 
- WHO group 1,3,4, or pulmonary 
hypertension 
- Genetic 
o Arrhythmogenic right 
ventricular dysplasia 
- Congenital heart disease 
- Isolated primary pulmonary or 
tricuspid valvular disease 
- Right ventricular infarction 
Specific cardiomyopathies 
- Infiltrative (amyloidosis) 
- Infectious/inflammatory 
o Sarcoidosis 
o Viral 
- Genetic 
o Hypertrophic cardiomyopathy 
o Restrictive cardiomyopathy  
 
 HFpEF is typically associated with hypertension, aging, coronary heart disease, diabetes, 
sleep disordered breathing, obesity, kidney disease, lung disease and anemia.32-36 While the signs 
and symptoms of all heart failure is similar, a HFpEF diagnosis should be considered in patients 
without significant epicardial coronary disease.37-39  
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1.5 Treatment Guidelines for Heart Failure 
The goals of treatment in heart failure are to control symptoms, improve health-related 
quality of life, and prevent hospitalization and death. In the past, most randomized control trials 
have predominantly enrolled patients with HFrEF, and all currently proven efficacious treatment 
options have only been demonstrated in this group. The US treatment guidelines recommend a 
combination of pharmacologic therapies for HFrEF patients.1 These treatments include: 
- Angiotensin-converting enzyme inhibitors (ACEI) or Angiotensin II-receptor blocker 
(ARB) 
- Beta-blocker 
- Diuretic 
- Mineralocorticoid receptor antagonist (aldosterone antagonists) 
- Certain vasodilators (hydralazine and isosorbide dinitrate) 
- Angiotensin receptor-neprilysin inhibitor (ARNI) 
- Sinoatrial node modulator 
The use of ACEI or ARB with beta-blocker in all patients with stable heart failure with 
reduced ejection fraction is recommended to reduce hospitalization and death. Diuretics and 
aldosterone antagonists can be added depending on the symptoms and severity of HF. Hydralazine 
and isosorbide dinitrate has been shown to be more effective in African Americans. In more recent 
years, ARNIs and sinoatrial node modulators have been approved for use. Figure 1.3 describes 
where the various treatment options affect the HFrEF disease pathway.1 
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Figure 1.3 – Pharmacological Approach to Different Disease Pathway in HFrEF1,40-41  
 
ACEI - Angiotensin-converting enzyme inhibitors; ARB - Angiotensin II-receptor blocker; ARNI - Angiotensin 
receptor-neprilysin inhibitor; and HFrEF- heart failure with reduced ejection fraction; MRA - mineralcorticoid 
receptor antagonist; LV – left ventricle; natriuretic peptides; SNS – sympathetic nervous system; RAAS – renin-
angiotensin aldosterone system 
Additionally, calcium channel blockers may be used to treat heart failure caused by high blood 
pressure, and antiarrhythmic agents may be used for patients with symptomatic ventricular 
arrhythmia.  
No clear efficacious treatment has been identified in the HFpEF population, thus far, and 
the completed clinical trials have only produced neutral results to date. Most treatments are largely 
directed toward associated conditions such as hypertension and symptoms such as edema. In the 
2013 American College of Cardiology / American Heart Association heart failure guidelines and 
the 2016 European Society of Cardiology heart failure guidelines, the recommendations for 
patients with HFpEF were limited due to lack of high quality data.1,42 The 2013 ACA/AHA HF 
guidelines states that: 
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- Systolic and diastolic hypertension should be controlled in accordance with published 
clinical guidelines to prevent morbidity.  
- Diuretic should be used to relieve symptoms due to volume overload 
However, with the high prevalence of HF and half of the patients suffering from HFpEF, there is 
an incredible opportunity for new treatment options in development to show clinical benefits in 
this patient group.  
1.6 Study Rationale 
Heart failure (HF) is a chronic disease with acute exacerbation that affects more than 5.8 
million people in the United States and more than 23 million worldwide. Despite advancement in 
medical therapy, the number of heart failure hospitalizations remains high, indicating a lack of 
disease control. With the increase in health care costs in general, the cost of heart failure 
treatment is predicted to increase by approximately 150% from 2012 to 2013.43 With 1.8 million 
physician office visits and 1 million hospital discharges for heart failure in 2010, it is the leading 
cause of hospitalization and 30 day readmission for the US elderly population.1,17,44 
Approximately 25% of patients hospitalized for heart failure are readmitted for any cause within 
1 month and 10% die of any cause within 30 days.45,46 In 2012, the Affordable Care Act 
established the Hospital Readmission Reduction Program which penalized hospitals with higher 
than expected 30-day readmission.3 Both the social and economic impact drives the need for a 
deeper understanding of heart failure and how to curb the disease burden.  
Furthermore, HF with preserved ejection fraction (HFpEF) is becoming a predominant 
form of HF in the developed world. It is also a disease that is poorly understood and under 
managed. In a previous study, healthcare resource utilization and medication use were described 
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in patients with heart failure (both HFrEF and HFpEF) in Central Texas. This study will be an 
extension of the previous study to pilot a predictive model to evaluate readmission for HFpEF 
patients based on the cohort identified. This model can be later applied to other cohorts to help 
providers make more informed decisions related to the disease management of HF. 
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CHAPTER 2: METHODOLOGY 
2.1 Study Objectives and Hypotheses 
To pilot a predictive model to evaluate hospital readmission for HFpEF patients: 
1. To determine whether being managed by a cardiologist affected the number of, time to, 
and odds of readmission (HF-related and all-cause) 
- H01.1 The difference in the number of readmissions (HF-related and all-cause) 
experienced by patients managed by a cardiologist and patients not managed by a 
cardiologist is not statistically significant. 
- H01.2 The difference in time to first readmission (HF-related and all-cause) experienced 
by patients managed by a cardiologist and patients not managed by a cardiologist is not 
statistically significant.  
- H01.3 The difference in odds for HF-related readmission experienced by patients 
managed by a cardiologist and patients not managed by a cardiologist is not statistically 
significant.  
2. To determine whether the number of comorbidities affect the number of, time to, and 
odds of readmission (HF-related and all-cause) 
- H02.1 The number of readmissions (HF-related and all-cause) experienced by patients 
will not differ significantly based on the number of comorbidities. 
- H02.2 The time to first readmission (HF-related and all-cause) experienced by patients 
will not differ significantly based on the number of comorbidities. 
- H02.3 The odds for HF-related readmission experienced by patients will not differ 
significantly based on the number of comorbidities. 
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3.  To determine whether the type of treatment (antiarrhythmics, beta-blockers, calcium 
channel blocker, renin-angiotensin aldosterone system inhibitor, or diuretic) affects the number, 
time, and odds of readmission (HF-related and all-cause) 
- H03.1 The number of readmissions (HF-related and all-cause) experienced by patients 
will not differ significantly based on the type of treatments (Antiarrhythmic, BB, CCB, 
RAAS inhibitor or Diuretic). 
- H03.2 The time to first readmission (HF related and all cause) experienced by patients 
will not differ significantly based on the type of treatments (Antiarrhythmic, BB, CCB, 
RAAS inhibitor or Diuretic). 
- H03.3 The odds for HF-related readmission experienced by patients will not differ 
significantly based on the type of treatments (Antiarrhythmic, BB, CCB, RAAS inhibitor 
or Diuretic). 
2.2 Study Design and Data Source 
In the previous study, data from existing Scott and White Health Plan (SWHP) medical 
and pharmacy claims, and electronic medical record (EMR) were utilized. SWHP is part of the 
Baylor Scott & White Health (BSWH) system, a non-profit integrated health system with 48 
acute care hospitals, 900 patient care sites, and approximately 6,000 physicians or other health 
care providers.  The date of admission of first hospitalization with a primary discharge diagnosis 
of HF was referred to as the index date. Baseline data from one year prior to the index date, 
details of the index admission, and healthcare resource utilization and costs for at least 1 year 
after discharge were analyzed. An ejection fraction measurement from an echocardiogram during 
index hospitalization was used to determine the patients with reduced versus preserved EF status. 
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Patients were followed until death, end of health plan enrollment, or end of study period (Oct 
2010 to Sept 2015).  
This is a retrospective, observational study of existing pharmacy and medical claims data 
to determine and specifically evaluate the effect of various factors: age, gender, provider, 
baseline number of inpatient admissions, number of comorbidities and baseline drug treatment 
classes (e.g. antiarrhythmic, beta blocker, calcium channel blocker, diuretic, RAAS-inhibiting 
agents) on number of readmissions, time to readmission, and odds of readmission. The summary 
of the study design is described in Figure 2.1. 
Figure 2.1 -  Study Design Schema 
 
 
 
  
 
 
 
The primary study endpoints are: 
o Number of Readmissions: All-Cause 
o Number of Readmissions – HF-related 
The secondary study endpoints are: 
o Time to First Readmission: All-Cause 
o Time to First Readmission: HF-related 
o Odds of HF-related Readmission 
09/30/2015 
Baseline period of at least 1-
year to assess demographics 
and comorbidities 
10/01/2010 10/01/2011 
Index date is the date of admission of 
first hospitalization with primary 
discharge diagnosis of HF 
09/30/2014 
Identification period for patients with inpatient 
admission with primary discharge diagnosis of 
heart failure 
Follow-up period of at least 1-
year post discharge to assess 
health care resource utilization  
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This study was approved by the University of Texas at Austin and the Baylor Scott & 
White Institutional Review Board following expedited review.  
2.3 Sample Selection 
Patients at least 18 years of age with an inpatient admission with a primary discharge 
diagnosis of HF (ICD-9-CM 428.xx) between October 1, 2011 and September 30, 2014 were 
identified (fiscal years FY2012-FY2014). The target population was health plan members that 
have heart failure with preserved ejection fraction. To be included in the study, patients had to be 
enrolled for 1 year prior to and at least 1 year after the index HF admission; the number of 
enrolled days was included as a covariate for patients with less than 2 full years of enrollment. In 
addition, patients were required to have a recent EF measurement from an echocardiogram that 
was ≥ 50%. Patients were excluded if they had an index length of stay (LOS) greater than 30 
days, a prior heart transplant or LV atrial defibrillator. A detailed list of inclusion and exclusion 
criteria is summarized below in Table 2.1.  
Table 2.1 - Patient Inclusion/Exclusion Criteria 
Inclusion Exclusion 
• ≥ 18 years of age 
• Hospital admission with primary 
discharge diagnosis of HF 
(International Classification of 
Diseases, Ninth Edition [ICD-9-
CM] 428.xx) 
• Continuous enrollment for 1 year 
prior to index admission, and at 
least 1 year after discharge 
• EF measurement from 
echocardiogram during index 
hospitalization >/= 50% 
• Previous HF hospitalization in 
preceding 12 months 
• Index Length of stay >30 days 
• Patients with reduced EF (EF < 50% 
during index hospitalization 
• Patients who are heart transplantation 
(history of heart transplant V42.1, 
heart transplantation ICD-9-A code 
37.5x and CPT-4 code 33945) or 
LVAD recipients (V43.21, 37.66, 
37.52, 37.54, 37.55, 37.63; 33975-
33983, 33993, 93750) 
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2.4 Study Variables 
Medical and pharmacy claims, and electronic medical record (EMR) data were captured 
from one-year pre-index to the end of the follow-up period. Baseline patient characteristics such 
as demographics, previous diagnosis of HF, and comorbidities were captured. The length of stay, 
costs, and ejection fraction (EF) measurement was described at index admission, and health care 
resource utilization (numbers, types, and costs of pharmacy and medical claims) was captured 
during follow-up for at least one-year post hospital discharge. Table 2.2 provides a detailed list 
of study variables, as well as health plan enrollment start and end dates for the HFpEF cohort.  
All patient-identifying data remained strictly confidential.  All data were maintained on 
secure, password protected Baylor Scott & White computers and only study investigators 
weregranted access to the study data.   
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Table 2.2 - Study Variables 
Baseline  
(one year prior to index) 
Index admission  Follow-up  
(≥1 year after discharge) 
• Age 
• Gender 
• Previous diagnosis of HF 
• Race/ethnicity 
• Comorbidities, including: 
 Coronary heart disease 
(ICD-9-CM: 410.x to 
414.x, also CPT codes for 
stent placement [G0291, 
C9600 to C6908], and 
coronary bypass surgery 
[S2205 to S2209]) 
 Diabetes mellitus (ICD-9-
CM 250.xx) 
 Hypertension (ICD-9-CM: 
401.x to 405.x, and/or 
presence of anti-
hypertensive medications) 
 Depression (ICD-9-CM: 
296.2 to 296.8, 300.4, 
309.1, and 311) 
 Dyslipidemia (ICD-9-CM: 
272.xx) 
 Valvular heart disease 
(ICD-9-CM: 424.0 to 
424.3) 
 Cardiomyopathy (ICD-9-
CM: 425.x) 
 Tobacco use disorder 
(ICD-9-CM: 305.1) 
 Cardiac dysrhythmias 
(ICD-9-CM: 427.x) 
 
• Length of stay 
• Cost of hospitalization 
• Ejection fraction 
measurement from 
echocardiogram 
• Number of inpatient 
admissions 
• Hospital days 
• Outpatient visits 
• Emergency room visits 
• Pharmacy dispenses 
(30 day supply; # of 
unique meds overall, 
then anti-arrhythmics, 
anti-hypertensives, 
digoxin, 
anticoagulants, calcium 
channel-blockers, beta-
blockers, anti-
lipidemic) 
• Costs (inpatient, 
outpatient, pharmacy) 
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2.5 Statistical Analysis 
Descriptive statistics were calculated for all variables.  Continuous variables are 
described using means and standard deviations (SD). Categorical variables are described using 
frequencies with percentages. Two sample t-test and Chi-square tests were also used to conduct 
bivariate analyses, specifically comparing the group of patients treated by a cardiologist  those 
who are not treated by cardiologist.  
Multivariate regression and Cox proportional hazard models were used to assess the 
association of the all-cause or heart failure-related readmission adjusting for demographic and 
clinical covariates. An estimated coefficient associated with readmission whose 95% confidence 
interval of the incident rate ratio (IRR) which excludes 1.0 highlights a significant association. A 
poisson regression model was selected to assess the associations with the number of 
readmissions, while the cox-proportion hazard model was used for time to first readmission. A 
logistic regression model was selected to determine the odds of heart-failure related 
readmissions. The covariates for all models included age and gender for demographics, provider 
(Non-Cardiologist/Cardiologist)  for objective 1,  baseline number of inpatient admissions to 
adjust for severity, the number of comorbidities for objective 2, and various medications 
including antiarrhythmics, beta-blockers, calcium channel blockers, RAAS-inhibiting agents 
(ACEI/ARBs), and diuretics for objective 3.  These are detailed in Table 2.3.  All analyses were 
performed using SAS version 9.4 software (SAS institute, Cary, North Carolina) with an alpha < 
0.05 as the criterion for statistical significance. 
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Table 2.3 - Predictive Models: 
Model 1: Poisson Regression (or related approach appropriate to the distribution such as 
negative binomial regression) for Number of Readmission All Cause = Age (#) + Gender 
(M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt Admissions + 
Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium Channel Blocker 
(Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Model 2: Cox Proportional Hazards  Regression** for Time to First Readmission All Cause = 
Age (#) + Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of 
Inpt Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Model 3: Poisson Regression (or related approach) for Number of HF related  Readmission = 
Age (#) + Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of 
Inpt Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Model 4: Cox Proportional Hazards  Regression** for Time to First Readmission HF= Age (#) 
+ Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt 
Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Model 5: Logistic Regression for odds of HF related  Readmission (yes/no)= Age (#) + 
Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt 
Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
*Comorbidities includes: Diabetes, Dyslipidemia, Hypertension, Coronary Heart Disease, Cardiomyopathy, 
Dysrhythmia, Valvular heart disease, Depression, Tobacco, Alcohol/other drug use 
** if proportional hazards assumptions are not met, Accelerated Failure Time models will be applied 
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CHAPTER 3: RESULTS 
3.1 Study Sample 
For the timeframe of October 2010 to September 2015, a total of 831 patients with a 
primary diagnosis of heart failure were identified. Among them, 601 (72%) had an index 
admission between October of 2011 and September of 2014 to allow for at least 1year pre- and 
post-index periods. After excluding minors (age <18) or those that met other exclusion criteria, a 
total of 264 patients were identified with preserved heart failure. Table 3.1 reports the sample 
attrition.  
Table 3.1 - Sample Selection 
Selection Criteria  n (%) 
Inpatient admission with primary 
diagnosis of heart failure between Oct 1, 
2010 and Sept 30, 2015  
831 (100%) 
Index admission between Oct 1, 2011 to 
Sept 30, 2014  
601 (72%) 
Inclusion and Exclusion Criteria Met  438 (53%) 
Ejection fraction ≥ 50  264 (32%) 
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3.2 Baseline Demographics and Clinical Characteristics 
Table 3.2 describes the baseline demographic and clinical characteristics for the 264 
patients meeting the inclusion criteria. 159 (60.2%) of the studied population were women, with a 
mean age at index of 79 years (SD 10.8). The average length of stay at index was 4.1 days with an 
average LV EF of 61.8%. Patients managed by a cardiologist were more likely to be male and had 
greater number of comorbidities, including diabetes, dyslipidemia, hypertension, coronary heart 
disease, cardiomyopathy, and valvular heart disease, than those without cardiologist.  
Table 3.3 describes the baseline healthcare resource utilization and medication use for the 
HFpEF patients. Overall, the patients had an average of 2.4 (SD 3.7) inpatient admissions, which 
equates to 5.4 hospital days (SD 9.9) one year before the index date. A total of 8% of patients were 
on antiarrhythmics, 56% were on beta-blockers, 37% were on calcium channel blockers, 49% were 
on ACE/ARBs, and 55% were on diuretics. Patients who visited a cardiologist during the baseline 
period had a higher number of inpatient admissions, inpatient hospital days, primary care visits, 
and ED visits than those without a cardiologist. They were also more likely to be on antiarrhythmic 
and beta blocker medications.  
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Table 3.2 - Baseline Demographic and Comorbidities 
 All  HFpEF 
(n=264) 
HFpEF w/o 
Card 
(n=77) 
HFpEF w/ Card 
(n=187) 
p-value 
Female, n  159 (60.2) 58 (75.3) 101 (54.0) 0.0013 
Age, years  79.0 (10.8) 79.5 (11.3) 78.83 (10.7) 0.4807 
Index admission length of 
stay, day 
4.1 (3.2) 4.3 (4.0) 4.0 (2.8) 0.9678 
Comorbidities, number of  3.7 (1.7) 2.3 (1.5) 4.3 (1.4) <0.0001 
Diabetes, n  125 (47) 29 (37.7) 96 (51.3) 0.0431 
Dyslipidemia, n  178 (67%) 35 (45.5) 143 (76.5) <0.0001 
Hypertension, n  236 (89%) 59 (76.6) 177 (94.7) <0.0001 
Coronary heart disease, n  133 (50%) 14 (18.2) 119 (63.6) <0.0001 
Cardiomyopathy, n  18 (7%) 1 (1.3) 17 (9.1) 0.0283 
Dysrhythmia, n  156 (59%) 22 (28.6) 134 (71.7) <0.0001 
Valvular heart disease, n  53 (20%) 4 (5.2) 49 (26.2) <0.0001 
Depression, n  45 (17%) 9 (11.7) 36 (19.3) 0.1374 
Tobacco use, n 21 (8%) 5 (6.5) 16 (8.6) 0.8027 
Alcohol/other drug use , n  9 (3%) 0 (0.0) 9 (4.8) 0.0624 
 
 
 
 
 
 
 
  
 
24 
Table 3.3 – Baseline Healthcare Resource Utilization and Medication Use 
 All  HFpEF 
(n=264) 
HFpEF w/o 
Card 
(n=77) 
HFpEF w/ Card 
(n=187) 
p-value 
Number of Inpt Admission 2.4 (3.7) 0.8 (2.2) 3.1 (4.0) <0.0001 
Inpt Hospital days 5.4 (9.9) 1.8 (4.3) 6.9 (11.1) <0.0001 
Primary care visits 13.2 (14.5) 5.9 (5.2) 16.3 (15.9) <0.0001 
ED visits  1.4 (2.0) 0.3 (0.6) 1.8 (2.3) <0.0001 
Anticoagulant 62 (23.5) 13 (16.9) 49 (25.2) 0.1044 
Antiarrhythmics 21 (8.0) 2 (2.6) 19 (10.2) 0.0447 
Beta-blockers 148 (56.1) 34 (44.2) 114 (61.0) 0.0124 
Calcium channel blockers 97 (36.7) 27 (35.1) 70 (37.4) 0.7168 
ACEI/ARBs 130 (49.2) 35 (45.5) 95 (50.8) 0.4296 
Diuretics  146 (55.3) 38 (49.4) 108 (57.8) 0.2119 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, ED- emergency department, Inpt- inpatient 
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3.3 Follow-up Healthcare Resource Utilization and Hospital Readmission 
Table 3.4 describes the one-year follow up healthcare resource utilization and 
readmissions. The HFpEF patients had an average of 3.8 (SD 5.0) inpatient readmissions, which 
equates to 7.3 hospital days (SD 12.1) one year after the index date. Nearly 51% of the patients 
had an all-cause readmission and 14% of patients had a HF-related readmission. Patients who saw 
a cardiologist during the pre-index period had a higher number of inpatient readmissions, inpatient 
hospital days, primary care visits, cardiologist visits, ED visits, and all-cause readmissions than 
those without a cardiologist. 
Figure 3.1 shows the breakdown of the number of patients with readmissions. Nearly 51% 
of the HFpEF patients (n=134) had an all-cause readmission during the 1-year post index, with 31 
patients having 3 or more readmissions. About 15% of the patients had a HF-related readmission 
(n=38) and 7 patients had 3 or more HF-related readmissions. 
Table 3.4 – One Year Follow Up Healthcare Resources Utilization and Readmission 
 All  HFpEF 
(n=264) 
HFpEF w/o 
Card 
(n=77) 
HFpEF w/ Card 
(n=187) 
p-value 
Number of Inpt Admission 3.8 (5.0) 2.9 (2.9) 4.2 (5.6) 0.0374 
Inpt Hospital days 7.3 (12.1) 5.1 (7.2) 8.2 (13.5) 0.0222 
Primary care visit 19.9 (14.3) 16.6 (13.4) 21.3 (14.4) 0.0014 
Cardiologist visits 5.8 (7.5) 3.3 (3.2) 6.69 (8.4) <0.0001 
ED visits  2.3 (2.6) 1.6 (1.8) 2.6 (2.8) <0.0001 
All cause readmitted 134 (50.8%) 27 (35.1%) 107 (57.2%) 0.0011 
HF readmitted 38 (14.4%) 7 (9.1%) 31 (16.6%) 0.1152 
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Figure 3.1 - Number of Patients with Readmission 
 
130, 49%
84, 32%
19, 7%
31, 12%
Number of Patients with All-Cause Readmissions
No Readmission 1 Readmission 2 Readmissions 2+ Readmissions
226, 85%
26, 10%
5, 2% 7, 3%
Number of Patients with HF-Related Readmissions 
No Readmission 1 Readmission 2 Readmissions 2+ Readmissions
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3.4 Predictive Modeling 
Table 3.5 shows the results of the Poisson regression models for predictors of the number 
all-cause readmissions. Being older (by 10 years) is associated with lower number of all- cause 
readmission with an incidence rate ratio (IRR) of 0.81 (p-value=0.0092). Having a cardiologist 
and having more comorbidities at baseline is associated with higher number of all-cause 
readmissions with an IRR of 2.21 (p-value=0.0003) and 1.19 (p-value=0.0038) respectively.  
 Table 3.6 shows the results of the Cox Proportional Hazard models for predictors of the 
time to first all-cause readmission. Patients who have cardiologists were 91% more likely to be 
readmitted at any time point during the study period (HR of 1.91, p-value=0.0040). The Kaplan-
Meier curve of time to first all-cause readmission for those with and without a cardiologist is 
illustrated in Figure 3.2.  
 Table 3.7 shows the results of the Poisson regression models for predictors of the number 
of heart failure-related readmissions. Being on a diuretic at baseline is associated with higher 
number of heart failure-related readmissions, with an incidence rate ratio of 2.84 (p-
value=0.0301). 
Table 3.8 shows the results of the Cox Proportional Hazard models for predictors of the 
time to first HF-related readmission. Patients who use beta-blockers were 83% less likely to be 
readmitted at any time point, while those who used calcium channel blockers were 71% less 
likely to be readmitted at any time point during the study period (HR of 0.17, p-value=0.0012 
and HR of 0.29, p-value=0.0054). The Kaplan-Meier curve of time to first HF-related 
readmission for those with and without a cardiologist is illustrated in Figure 3.3.  
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Table 3.9 shows the results of the logistic regression models for predictors of the odds of 
heart failure-related readmissions. None of the variables were predictive of the odds of having 
another heart failure-related readmission. 
 
Table 3.5 – Model 1 to Evaluate Predictors of Number of All-Cause Readmission  
Poisson Regression (or related approach appropriate to the distribution such as negative binomial 
regression) for Number of Readmission All Cause = Age (#) + Gender (M/F) + Provider (Non-
Cardiologist/Cardiologist) + Baseline Number of Inpt Admissions + Comorbidity* (#) + 
Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium Channel Blocker (Y/N) + RAAS-
inhibiting agents (Y/N) + Diuretics (Y/N) 
 
Variable IRR 95% CI Chi-Square p-value 
Age (10 year) 0.81 0.69-0.95 6.78 0.0092 
Female 1.05 0.74-1.51 0.08 0.7720 
Cardiologist 2.21 0.49-0.05 12.89 0.0003 
Number of Inpt 
admission 
1.04 0.99-1.10 2.87 0.0851 
Number of 
comorbidities 
1.19 1.06-1.34 8.39 0.0038 
Antiarrhymic use 0.81 0.42-1.54 0.42 0.5157 
Beta-blocker use  0.95 0.62-1.45 0.07 0.7969 
CC blocker use 0.91 0.52-1.33 0.25 0.6144 
ACEI/ARB use 1.20 0.82-1.75 0.88 0.3474 
Diuretic use 1.15 0.76-1.74 0.44 0.5056 
 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, BB- Beta blocker, CCB- Calcium Channel blocker, Inpt- 
Inpatient 
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Table 3.6 – Model 2 to Evaluate Predictors of Time to First All-Cause Readmission  
Cox Proportional Hazards  Regression** for Time to First Readmission All Cause = Age (#) + 
Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt 
Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Variable HR 95% CI Chi-Square p-value 
Age (10 year) 0.87 0.75-1.02 3.09 0.0789 
Female 1.04 0.72-1.51 0.05 0.8247 
Cardiologist 1.91 1.23-2.96 8.30 0.0040 
Number of Inpt 
admission 
1.03 0.98-1.07 1.18 0.2770 
Number of 
comorbidities 
1.12 0.99-1.26 3.25 0.0712 
Antiarrhythmic use 1.07 0.59-1.92 0.05 0.8300 
Beta-blocker use  0.80 0.51-1.23 1.06 0.3034 
CC blocker use 0.91 0.62-1.33 0.26 0.6109 
ACEI/ARB use 1.20 0.80-1.78 0.78 0.3767 
Diuretic use 1.49 0.95-2.33 3.06 0.0803 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, BB- Beta blocker, CCB- Calcium Channel blocker, Inpt- 
Inpatient 
 
 
Figure 3.2 – Time to First All-Cause Readmission by Cardiologist Status 
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Table 3.7 – Model 3 to Evaluate Predictors of Number of HF-Related Readmission  
Poisson Regression (or related approach) for Number of HF related  Readmission = Age (#) + 
Gender (M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt 
Admissions + Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium 
Channel Blocker (Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
 
Variable IRR 95% CI Chi-Square p-value 
Age (10 year) 0.89 0.65-1.22 0.54 0.4612 
Female 1.07 0.50-2.31 0.03 0.8631 
Cardiologist 1.69 0.70-4.07 1.38 0.2404 
Number of Inpt 
admission 
0.98 0.88-1.10 0.09 0.7685 
Number of 
comorbidities 
1.31 0.99-1.73 3.63 0.0568 
Antiarrhythmic use 0.85 0.22-3.35 0.05 0.8155 
Beta-blocker use  0.74 0.30-1.83 0.43 0.5112 
CC blocker use 1.04 0.47-2.32 0.01 0.9160 
ACEI/ARB use 0.74 0.33-1.67 0.54 0.4639 
Diuretic use 2.84 1.11-7.29 4.70 0.0301 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, BB- Beta blocker, CCB- Calcium Channel blocker, Inpt- 
Inpatient 
 
 
Table 3.8 – Model 4 to Evaluate Predictors of Time to First HF-related Readmission  
Cox Proportional Hazards Regression** for Time to First Readmission HF= Age (#) + Gender 
(M/F) + Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt Admissions + 
Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium Channel Blocker 
(Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N) 
Variable HR 95% CI Chi-Square p-value 
Age (10 year) 0.76 0.55-1.06 2.56 0.1096 
Female 1.24 0.54-2.84 0.26 0.6087 
Cardiologist 2.56 0.83-7.88 2.69 0.1007 
Number of Inpt 
admission 
1.02 0.88-1.17 0.06 0.8063 
Number of 
comorbidities 
1.16 0.81-1.67 0.64 0.4226 
Antiarrhythmic use 2.40 0.69-8.30 1.89 0.1685 
Beta-blocker use  0.17 0.06-0.50 10.42 0.0012 
CC blocker use 0.29 0.12-0.69 7.75 0.0054 
ACEI/ARB use 2.48 0.91-6.72 3.16 0.0754 
Diuretic use 2.08 0.84-5.17 2.50 0.1135 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, BB- Beta blocker, CCB- Calcium Channel blocker, Inpt- 
Inpatient 
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Figure 3.3 – Time to First HF-Related Readmission by Cardiologist Status 
 
 
Table 3.9 – Model 5 to Evaluate Predictors of Odds of HF-Related Readmission  
Logistic Regression for Number of HF related Readmission (yes/no)= Age (#) + Gender (M/F) + 
Provider (Non-Cardiologist/Cardiologist) + Baseline Number of Inpt Admissions + 
Comorbidity* (#) + Antiarrhythmic (Y/N) + Beta-Blocker (Y/N) + Calcium Channel Blocker 
(Y/N) + RAAS-inhibiting agents (Y/N) + Diuretics (Y/N); 
 
Odds Ratio Estimates  
Effect OR 95%  
Confidence Limits 
p-value 
Age (10 year) 0.782 0.570 1.073 0.1278 
Female 0.711 0.333 1.516 0.3776 
Cardiologist 1.748 0.703 4.345 0.2291 
Number of Inpt admission 1.001 0.902 1.109 0.9901 
Number of comorbidities 1.221 0.949 1.571 0.1213 
Antiarrhythmic use 1.333 0.401 4.432 0.6394 
Beta-blocker use  0.863 0.356 2.092 0.7436 
CC blocker use 1.429 0.649 3.145 0.3752 
ACEI/ARB use 0.847 0.389 1.842 0.6748 
Diuretic 2.238 0.867 5.778 0.0959 
ACEI- Angiotensin-converting enzyme inhibitors, ARB- Angiotensin II-receptor blocker, BB- Beta blocker, CCB- Calcium Channel blocker, Inpt- 
Inpatient 
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3.5 Summary of Results 
 Results of all hypothesis tested are reported in Table 3.10. A higher number of and shorter 
time to all-cause readmissions was associated with patients who have a cardiologist (Objective 1). 
Being on a diuretic at baseline was associated with a higher number of heart failure-related 
readmissions while being on beta-blockers and calcium channel blockers was associated with a 
longer time to first heart failure-related readmission (Objective 2). A higher number of all-cause 
readmissions was associated patients having more comorbidities (Objective 3) 
 
 
 
 
Table 3.10 – Results of Hypothesis Test 
Objectives and Alternate Hypothesis (H1) Results 
Objective 1: To determine whether being managed by a cardiologist affected the number of, 
time to, and odds of readmission (HF-related and all-cause) 
H11.1 The difference in the number of readmissions (HF-related and all-
cause) experienced by patients managed by a cardiologist and patients not 
managed by a cardiologist is statistically significant. 
Failed to Reject 
(all-cause 
readmission) 
H11.2 The difference in time to first readmission (HF-related and all-
cause) experienced by patients managed by a cardiologist and patients not 
managed by a cardiologist is statistically significant.  
Failed to Reject 
(all-cause 
readmission) 
H11.3 The difference in odds for HF-related readmission experienced by 
patients managed by a cardiologist and patients not managed by a 
cardiologist is statistically significant.  
Rejected 
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Table 3.10 – Results of Hypothesis Test (continued) 
 
Objective 2: To determine whether the number of comorbidities affect the number of, time to, 
and odds of readmission (HF-related and all-cause) 
H12.1 The number of readmissions (HF-related and all-cause) experienced 
by patients will differ significantly based on the number of comorbidities. 
Failed to Reject 
(all-cause 
readmission) 
H12.2 The time to first readmission (HF-related and all-cause) 
experienced by patients will differ significantly based on the number of 
comorbidities. 
Rejected  
H12.3 The odds for HF-related readmission experienced by patients will 
differ significantly based on the number of comorbidities. 
Rejected 
Objective 3: To determine whether the type of treatment (antiarrhythmics, beta-blockers, 
calcium channel blocker, renin-angiotensin aldosterone system inhibitor, or diuretic) affects 
the number, time, and odds of readmission (HF-related and all-cause) 
H13.1 The number of readmissions (HF-related and all-cause) experienced 
by patients will differ significantly based on the type of treatments 
(Antiarrhythmic, BB, CCB, RAAS inhibitor or Diuretic). 
Failed to Reject 
(HF readmission 
for Diuretics) 
H13.2 The time to first readmission (HF related and all cause) experienced 
by patients will differ significantly based on the type of treatments 
(Antiarrhythmic, BB, CCB, RAAS inhibitor or Diuretic). 
Failed to Reject 
(HF readmission 
for BB and CCB) 
H13.3 The odds for HF-related readmission experienced by patients will 
differ significantly based on the type of treatments (Antiarrhythmic, BB, 
CCB, RAAS inhibitor or Diuretic). 
Rejected 
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CHAPTER 4: DISCUSSION AND CONCLUSION 
4.1 Discussion 
The purpose of this study was to assess the effects of demographic, clinical characteristics, 
healthcare resource utilization and medication on number of readmissions, time to readmission, 
and odds of readmission for patients with HFpEF. The study focuses on patients with HFpEF due 
to the limited research and treatment options in this cohort compared to HFrEF.1,19,20,42 The study 
is consistent with current literature where HFpEF patients were more likely to be female (60%) 
and older (mean age at index of 79 years) given the pathophysiology of the disease which increases 
with age.47-49 Patients had an average of 3.7 comorbidities, with 67% suffering from dyslipidemia, 
89% from hypertension, and 59% from dysrhythmia. The number of comorbidities were higher 
among those treated by cardiologists, which is supportive of previous findings where 
multimorbidity is common in HFpEF patients.19-20 Furthermore, HFpEF is typically associated 
with hypertension, aging, coronary heart disease, diabetes, sleep disordered breathing, obesity, 
kidney disease, lung disease and anemia.32-36 Thus, it is no surprise that a higher number of all-
cause readmissions was associated with patients having more comorbidities. 
This studied shows that patients who have a cardiologist were associated with a higher 
number all-cause readmissions and a shorter time to all-cause readmissions. While this may be a 
predictive factor, it is not believed to be causative. Based on the bivariate analysis, patients with 
cardiologist care appear to be at higher risk and with greater number of comorbidities, including 
diabetes, dyslipidemia, hypertension, coronary heart disease, cardiomyopathy, and valvular heart 
disease than those without a cardiologist. Although our model adjusted for various factors such as 
age, number of comorbidities, and treatments, it was not able to account for severity of conditions. 
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A study of 275 patients showed that patients under generalist care had less severe cardiac disease 
than those cared for by cardiologist. The study suggested that any differences in outcomes between 
the two groups of patients were likely due to the severity of underlying disease and co-morbidites 
rather than quality of care that was provided by the physicians. 51 Furthermore, another study of 
1,298 patients based out of the San Francisco Bay area found that patients were less likely to 
receive care from a cardiologist if they were black, had less income, or were older. 52 These 
socioeconomic factors are well-established factors for access to healthcare resources, which were 
not in our predictive models for hospital readmission.  
None of the typical HF treatments were associated with the number of all-cause 
readmissions. While the ACEI or ARB with beta-blockers are recommended in all patients with 
stable heart failure with reduced ejection fraction, there is no proven treatment for HF patients 
with preserved EF. This is evident in the study where ACEI/ARBs, beta-blockers, calcium channel 
blockers, and diuretics were utilized by only half of the patients. The best guidance from the 
ACC/AHA is to manage hypertension to prevent morbidity and use diuretics to relieve symptoms. 
There was evidence that suggests being on diuretic at baseline is associated with higher number of 
heart failure-related readmission. However, this may also be confounded by patient disease 
severity since diuretics and aldosterone antagonists are added to help manage the symptoms and 
severity of HF.1  
Just over half of the patients suffered from an all-cause readmission, which is consistent 
with the hospitalization rate from the OPTIMIZE HF Registry, a large national registry and 
performance improvement program for patients hospitalized for HF.50 This illustrates a significant 
unmet need and opportunity for improvement, especially given the payment incentive from the 
Hospital Readmission Reduction Program. In a study evaluating strategies to reduce 30-day 
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readmissions in older patients hospitalized with heart failure, the author recognizes that predictors 
and strategies are limited.53 It’s clear that readmission may not be readily explained by simple 
deterministic understanding of risk, and our pilot supports this conclusion. Thus, an integrated 
view of patient risk, recovery after hospitalization, and innovative treatment for patients with 
HFpEF is needed to effectively manage the disease.  
4.2 Limitations 
Due to the nature of the retrospective observational study, limitations should be taken 
into consideration for the interpretation of findings. First, data utilized in this study were 
collected for hospital administrative purposes and not for research. Therefore, administrative 
data may not always accurately capture patient and clinical characteristics. In addition, it is well 
known that studies using administrative data cannot confirm ingestion of prescribed medications; 
the current study can only determine that the prescription was filled at the pharmacy. 
Multivariate regression and Cox proportional hazard models are common methodologies to 
analyze associations, but causations may require more intensive prospective randomized control 
studies. Finally, the patient population is predominantly made up of a small set of patients in 
central Texas, which may not be representative or generalizable to broader population. The small 
sample size limits the number and depth of predictive factors tested in the analysis. Thus, there 
may be confounding factors not considered and the results are hypothesis generating in nature.  
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4.3 Conclusion 
As the United States population continues to age and healthcare cost rises, innovative 
management of the prevalent HFpEF condition is needed to curb the progression of the disease 
and the strain on the healthcare system from readmission. This study demonstrated that all-cause 
and heart failure-related readmissions signify an unmet need. The pilot predictive models show 
that various factors associated with higher risk patients such as those with cardiologist 
management, more comorbidities and use of diuretics may be associated with increased hospital 
readmissions. Further research is needed to take a more comprehensive look at the predictors of 
hospital readmissions over a larger patient cohort while controlling for more confounding factors 
to identify opportunities for improvement.  
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